Form 4: REVB Director Sells Shares for Tax Obligations
Insider Transaction Report
Revelation Biosciences Director Jess Roper sold 1,591 shares of common stock at a weighted average price of $1.85 to cover tax obligations following a restricted stock award vesting.
Summary
- Director Jess Roper of Revelation Biosciences, Inc. (REVB) sold 1,591 shares of common stock.
- The sale occurred on February 3, 2026, at a weighted average price of $1.85 per share, with individual transactions ranging from $1.84 to $1.88.
- The transaction was mandatory and executed by the issuer on behalf of Mr. Roper solely to satisfy tax obligations arising from the vesting of restricted stock awards.
- Mr. Roper did not exercise investment discretion regarding this sale.
- Following the transaction, Mr. Roper beneficially owns 12,828 shares of common stock.
- All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. The sale was mandatory for tax purposes, not a discretionary decision by the director, thus it does not signal a change in confidence or company fundamentals.
Industry Context
StockSavvy.ai notes that mandatory sales by insiders to cover tax liabilities upon restricted stock vesting are a common occurrence and generally do not reflect a change in management's outlook on the company's prospects or broader industry trends. This transaction is specific to the individual's compensation structure rather than a strategic move.
Stakeholder Impact
- Minimal impact on shareholders as the sale was mandatory for tax purposes and relatively small, not indicating a lack of confidence from the director.
Key Dates
| Date | Description |
|---|---|
| January 28, 2026 | Effective date of 1-for-4 reverse stock split. |
| February 3, 2026 | Date of transaction (sale of common stock). |
| February 5, 2026 | Date of filing signature. |
Recommendation
holdThe transaction is a mandatory sale to cover tax obligations related to restricted stock vesting, which is a routine event for insiders. It does not reflect a discretionary decision by the director regarding the company's future prospects, thus it provides no new fundamental information to warrant a change in investment recommendation. Investors should hold and look for more substantive company updates.
Keywords
Revelation Biosciences, REVB, Jess Roper, Form 4, Insider Trading, Stock Sale, Tax Obligation, Restricted Stock, Reverse Stock Split
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.